Core Viewpoint - Dongfang Ocean's subsidiary, Aiveke Biotechnology Co., Ltd., has received regulatory approval for its procalcitonin (PCT) testing kit, marking a significant advancement in its product offerings [1] Group 1 - The PCT testing kit is developed using a fluorescence immunochromatography method [1] - The kit has been approved by the Shandong Provincial Drug Administration and has received a medical device registration certificate [1] - The registration certificate number is Lu Xie Zhu Zheng 20252400747, with a validity period from December 11, 2025, to December 10, 2030 [1]

Group 1 - Rongchang Biotech plans to repurchase shares worth between 20 million and 40 million yuan, with a maximum price of 95 yuan per share, aiming to buy back approximately 21,050 to 42,110 shares, representing about 0.04% to 0.07% of total share capital [1] - Nanya New Materials intends to raise no more than 900 million yuan through a private placement for AI computing power-based high-frequency high-speed copper-clad laminate R&D and working capital [2] - Xiechuang Data has signed a strategic cooperation agreement with Ping An Financial Leasing, aiming for a cooperation scale of 2 billion yuan over three years [3] Group 2 - Chuangshi Technology's controlling shareholder is under investigation and has been placed under detention, having resigned from all positions in the company [4] - Deep Kangjia A has reported overdue shareholder loans to Yikang Technology and Chuzhou Kangxin, totaling approximately 233 million yuan and 395 million yuan respectively, due to repayment issues [5] - Ningbo Yuanyang announced the resignation of two directors due to work adjustments [6] Group 3 - China Merchants Energy has delivered the world's first methanol dual-fuel VLCC oil tanker, with 15 oil tanker orders in hand [7] - Tianyu Co., Ltd. has received a drug registration certificate for hydrochloride trazodone tablets, which are used for treating depression [8] - Haizheng Pharmaceutical has received FDA approval for clinical trials of HS387 tablets for treating advanced solid tumors [9] Group 4 - Warner Pharmaceuticals has obtained a drug registration certificate for isoproterenol hydrochloride injection, used for treating shock and complete atrioventricular block [10] - Hekang New Energy's subsidiary received a government subsidy of 1.5 million yuan, which accounts for 14.57% of the company's latest audited net profit [11] - Duku Culture is planning a change in company control, with stock suspension expected for no more than two trading days [12] Group 5 - Haisco has received acceptance for an IND application for HSK46575 tablets for prostate cancer treatment [13] - *ST Xinyan is executing a capital reserve transfer to increase share capital, resulting in a stock suspension [14] - Nanjing Public Utilities is transferring a 45% stake in a subsidiary for 23.6443 million yuan [15] Group 6 - Action Education plans to repurchase shares worth between 20 million and 25 million yuan, with a maximum price of 45 yuan per share [16] - Bai'ao Tai has received government subsidies totaling 29 million yuan [18] - Weisi Medical intends to sell assets worth 119 million yuan, expecting a profit impact of approximately 10 million yuan [19] Group 7 - Tongyu Communications plans to increase capital by 10 million yuan to introduce investment from Wuchuang Institute [20] - Dongtu Technology's subsidiary is introducing strategic investor Guofeng Investment Fund with a capital increase of 11 million yuan [21] - China General Nuclear Power Technology's shareholder is facing a judicial auction of 2.91% of the company's shares [22] Group 8 - Nanshan Aluminum plans to repurchase shares worth between 300 million and 600 million yuan, with a maximum price of 7.52 yuan per share [23] - Yipin Hong's controlling shareholder has committed to transferring 9.07% equity in Arthrosi without compensation [24] - Sanli Pharmaceutical has signed a technology transfer contract worth 200 million yuan with Hainan University [25] Group 9 - Xin Nuo Wei plans to jointly invest 450 million yuan with Zhongqi Pharmaceutical to establish a joint venture focusing on innovative metabolic drugs [26] - Li Qun Co. has been approved to issue 1 billion yuan in medium-term notes to optimize debt structure and supplement working capital [27] - Dongfang Ocean's subsidiary has received a medical device registration certificate for a procalcitonin test kit [28] Group 10 - Tibet Mining's chairman has resigned due to work adjustments [29] - Wantai Biological's subsidiary has been shortlisted for a national immunization program vaccine procurement project, with a bid price of 27.5 yuan [30] - Xingfu Blue Sea has appointed Zhang Chen as the new deputy general manager [31] Group 11 - Changyuan Donggu has elected Li Yixuan as the vice chairman of the board [32] - Ningbo Huaxiang's subsidiary has signed a strategic cooperation agreement with Dahuang Robotics for collaboration in humanoid robot development [33] - Yongda Co. has been pre-selected for a procurement project worth approximately 350 million yuan [34] Group 12 - Fuan Pharmaceutical's subsidiary has received a drug registration certificate for hydrochloride trazodone tablets [35] - Nanjing Food reported a 71.03% year-on-year decrease in net profit for November due to rising raw material costs [36] - Changqing Technology's special polymer monomer project has commenced production [37]

（记者 曾健辉） 截至发稿，东方海洋市值为47亿元。 每经头条（nbdtoutiao）——新能源重卡爆单了，11月销量同比增长178%！两班倒都供不应求，客户直 接进厂催单，这情景十年难遇 每经AI快讯，东方海洋（SZ 002086，收盘价：2.4元）12月22日晚间发布公告称，山东东方海洋科技股 份有限公司全资子公司艾维可生物科技有限公司自主研发的降钙素原（PCT）测定试剂盒于近日取得了 山东省药品监督管理局的注册批准，获得医疗器械注册证。产品名称为"降钙素原测定试剂盒"。 2025年1至6月份，东方海洋的营业收入构成为：水产加工业占比73.14%，体外诊断占比10.19%，海水 养殖业占比9.97%，其他业务--租赁及其他占比6.7%。 ...

Core Viewpoint - The company announced that its wholly-owned subsidiary, Aiveke Biotechnology Co., Ltd., has received a medical device registration certificate from the Shandong Provincial Drug Administration for its self-developed procalcitonin (PCT) assay kit, which is approved for market launch [1] Group 1 - The PCT assay kit is designed for the quantitative detection of procalcitonin levels in human serum, plasma, and whole blood samples [1] - The product has not yet been put into production, and its actual sales will be influenced by market expansion efforts and actual market demand [1] - The impact of Aiveke Biotechnology Co., Ltd. on the company's performance this year has been minimal, and future impacts remain uncertain [1]

证券代码：002086 证券简称：东方海洋 公告编号：2025-068 山东东方海洋科技股份有限公司 关于全资子公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示： 山东东方海洋科技股份有限公司（以下简称"公司"）全资子公司艾维可生物 科技有限公司自主研发的降钙素原（PCT）测定试剂盒（荧光免疫层析法）于近 日取得了山东省药品监督管理局的注册批准，获得医疗器械注册证，具体情况如 下： 一、产品信息 | 产品名称 | 降钙素原（PCT）测定试剂盒（荧光免疫层析法） | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 注册证编号 | 鲁械注准 20252400747 | | | | | | | | 注册人名称 | 艾维可生物科技有限公司 | | | | | | | | 注册证有效期 | 年 月 日 2025 11 10 | 12 | 月 | 日至 | 2030 | 12 | 年 | | 适用范围 | 用于体外定量检测人血清、血浆、全血样本中的降钙素 ...

转自：前瞻产业研究院 以下数据及分析来自于前瞻产业研究院深海科技研究小组发布的《中国海洋经济产业发展状况调研与投 资战略分析报告》 行业主要上市公司：中国船舶(600150.SH);中船防务(600685.SH);振华重工(600320.SH);中海油服 (601808.SH);中国海防(600764.SH);海兰信(300065.SZ);中天科技(600522.SH)等 本文核心数据：上市公司业务布局;上市公司业绩对比 深海科技行业上市公司汇总 中国深海科技上市公司数量较多，已形成完整产业链，涵盖高端装备制造、油气勘探服务、深海通信与 探测多个领域。以中国船舶、中海油服等为代表的央企龙头，主导深海钻井平台、特种船舶等重大装备 制造;中天科技、东方电缆在海底光缆电缆领域技术领先;海兰信、中国海防则聚焦水下探测与国防科 技。这些企业作为国家海洋战略的核心力量，正持续推动深海资源开发与关键技术自主化，展现出强大 的综合竞争力。 各公司公告 图表 1: 2025年中国深海科技产业上市公司汇总(一) | 公司简称 | 股票代码 | 要点 | 关联度 | | --- | --- | --- | --- | | 中国船舶 ...

（文章来源：证券日报） 证券日报网讯 12月15日晚间，东方海洋发布公告称，山东东方海洋科技股份有限公司子公司质谱生物 科技有限公司自主研发的甲氨蝶呤检测试剂（液相色谱-串联质谱法）于近日取得了山东省药品监督管 理局的注册批准，获得医疗器械注册证。 ...

证券代码：002086 证券简称：东方海洋 公告编号：2025-067 | 产品名称 | 甲氨蝶呤检测试剂（液相色谱-串联质谱法） | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 注册证编号 | 鲁械注准 20252400746 | | | | | | | | | 注册人名称 | 质谱生物科技有限公司 | | | | | | | | | 注册证有效期 | 月 月 2025 12 11 | 年 | 年 | 12 | 日 | 日至 | 2030 | 10 | | 适用范围 | 用于体外定量检测人体血清或血浆中甲氨蝶呤的含量。 | | | | | | | | 山东东方海洋科技股份有限公司 关于子公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示： 1. 质谱生物科技有限公司今年对公司的业绩影响较小，本次获批上市的甲 氨蝶呤检测试剂（液相色谱-串联质谱法）的投产及对公司业绩的后续影响具有 不确定性，请广大投资者注意投资风险。 2. ...

产品名称：甲氨蝶呤检测试剂（液相色谱-串联质谱法），注册证编号：鲁械注准 20252400746，适用 范围：用于体外定量检测人体血清或血浆中甲氨蝶呤的含量。 格隆汇12月15日丨东方海洋(002086.SZ)公布，公司子公司质谱生物科技有限公司自主研发的甲氨蝶呤 检测试剂(液相色谱-串联质谱法)于近日取得了山东省药品监督管理局的注册批准，获得医疗器械注册 证。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002086 证券简称：东方海洋 公告编号：2025-066 山东东方海洋科技股份有限公司 关于召开2025年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、召开会议的基本情况 1、股东会届次：2025年第二次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深圳证 券交易所上市公司自律监管指引第1号一一主板上市公司规范运作》等法律、行政法规、部门规章、规 范性文件及《公司章程》的有关规定。 4、会议时间： （4）根据相关法规应当出席股东会的其他人员。 （1）现场会议时间：2025年12月26日09:30 8、会议地点：山东省烟台市莱山区澳柯玛大街18号公司会议室。 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为2025年12月26日9:15-9:25， 9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体时间为2025年12月26日9:15 至 ...